Inotek Pharmaceuticals Corp (ITEK) Closes Week With A Bang After Positive Phase 2 Study Results

The shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) have declined by 35.93% year-to-date and are currently trading at $18.62. The hedge fund managers tracked by Insider Monkey had interesting activity in the stock of the biopharmaceutical company during the first quarter. Out of the 737 funds in our database, 21 hedge funds held positions worth $101.27 million in the company compared to holdings of $124.93 million from 13 investors at the end of the fourth quarter. It is important to consider that the shares of Aerie Pharmaceuticals grew by 7.85% during the first quarter, which makes the depreciation in net investments even more significant, despite the fact that the number of funds holding positions increased by eight. James E. Flynn’s Deerfield Management held the largest position in the company of those funds, with 606,118 shares valued at $19.00 million.

Why are we interested in the 13F filings of a select group of hedge funds? We use these filings to determine the top 15 small-cap stocks held by these elite funds based on 16 years of research that showed their top small-cap picks are much more profitable than both their large-cap stocks and the broader market as a whole. These small-cap stocks beat the S&P 500 Total Return Index by an average of nearly one percentage point per month in our backtests, which were conducted over the period of 1999 to 2012. Moreover, since the beginning of forward testing from August 2012, the strategy worked just as our research predicted, outperforming the market every year and returning 139% over the last 34 months, which is more than 80 percentage points higher than the returns of the S&P 500 ETF (SPY) (see more details).

Disclosure: None